Bacilus subtilis cells selected for their resistance to rhodamine 6G demonstrated a multidrug-resistance (MDR) phenotype resembling that of mammalian MDR cells. Like MDR in mammalian cells, MDR in bacteria was mediated by the efflux of the drugs from the cells. The bacterial multidrug efflux system transported similar drugs and was sensitive to similar inhibitors as the mammalian multidrug transporter, P-glycoprotein. The gene coding for the bacterial multidrug transporter, like the P-glycoprotein gene in mammalian MDR cells, was amplified in the resistant bacteria. On the other hand, the bacterial multidrug transporter showed no sequence similarity to P-glycoprotein but exhibited an obvious homology to tetracycline efflux pumps and carbohydrate-ion symporters. These results show that the transport of structurally unrelated molecules can be mediated by members of different families of membrane transporters.
Mammalian cells selected in culture for resistance to various lipophilic cytotoxic drugs often demonstrate resistance not only to the selective agent but also to a large group of apparently unrelated toxic compounds. This phenomenon, called multidrug resistance (MDR) , is based on active efflux of drugs from the cells, performed by a membrane ATPase pump, P-glycoprotein (reviews in refs. 1 and 2). In MDR cells, the mdrl gene coding for this protein is frequently amplified (1) . Overexpression of the P-glycoprotein gene is believed to be responsible for clinical drug resistance in many tumors.
The most intriguing question in the area of MDR is the mechanism of extremely broad chemical specificity of P-glycoprotein. Its substrates have almost nothing in common, except that most of them bear positive electric charge and all of them are moderately hydrophobic. Some substances, such as reserpine and verapamil, are potent inhibitors of P-glycoprotein activity, apparently by a competition mechanism (3, 4) . P-glycoprotein belongs to a large family of membrane ATPase pumps both of eukaryotic and of prokaryotic origin (2) . It is, however, the only member of this family with a proven ability to transport multiple drugs. Even close homologues ofP-glycoprotein-the mammalian mdr2 gene product (5) and the yeast STE6 protein (6)-do not share this property. Here we describe MDR in Gram-positive bacteria and characterize the gene of a bacterial multidrug transporter.s MATERIALS AND METHODS Bacteria and Plasmids. Bacillus subtilis BD170 (trpC2, thr-S) and BD224 (trpC2, thr-S, recE4), Escherichia coli JM103, B. subtilis plasmids pCB20 (7) and pUB110, E. coli plasmids pUC19 and pBluescript KS(+) (Stratagene), and shuttle plasmid pMK3 (8) were used in this work.
Selection of Resistant Bacteria and Sensitivity Assay. BD170 bacteria were selected with rhodamine 6G in the liquid antibiotic medium 3 (Difco) supplemented with 0.4% glucose.
Bacteria were grown at 370C with the drug at 0.5, 1, 2, 3, and 4,g/ml, consecutively. The cultures were diluted 1:100 with fresh drug-containing medium every 1-2 days. The drug concentration was increased every 1-2 weeks.
The sensitivity ofbacteria to various drugs was assessed by inoculating overnight bacterial cultures (1:100) into 96-well plates containing serial 1:1.5 dilutions of the drugs in the liquid medium described above. The minimal concentration of drug completely inhibiting bacterial growth was evaluated by observing medium turbidity after 6 hr of incubation at 37TC. In some experiments the medium was supplemented with reserpine (5 ,ug/ml) or verapamil (25 pug/ml), which increased drug sensitivity (see Results). These compounds had no effect when the test was performed not in liquid medium but on agar plates, presumably due to their binding to the agar gel matrix. All the drugs were purchased from Sigma and used as 1 mg/ml stock solutions.
Accumulation and Efflux of Ethidium Bromide. Bacteria in logarithmic growth were collected by centrifugation, resuspended in Spizizen salt medium to an OD6wo of0.2, and placed in the fluorimeter cuvette. Ethidium bromide was added (2 ,g/ml) and the change in fluorescence intensity (Aexcite, 530 nm; Aemit, 600 nm) was recorded on a Hitachi MPF-4 spectrofluorimeter equipped with a plotter. Fluorescence intensity is proportional to the quantity of the intracellular dye, since ethidium fluorescence is dramatically enhanced by the binding to intracellular components, especially to nucleic acids. A similar assay was described previously (9) . For measurement of ethidium efflux, bacteria were incubated with the dye (2 ,ug/ml) and reserpine (5 ,gg/ml) for 15 min, pelleted in a microcentrifuge, quickly resuspended in dyefree Spizizen medium, and placed in the fluorimeter cuvette. In some experiments protoplasts prepared from bacteria by lysozyme treatment (1 mg/ml, 1 hr, 37°C) were used. In these cases all measurements were performed in 0.5 M sucrose/20 mM MgCl2/20 mM sodium maleate, pH 6.5. ATP was mea-Conventional DNA manipulation procedures were performed (13) . Transduction mapping of the B. subtilis genome was performed by using a collection of Tn917-transformed bacteria (14) and the phage AR9.
To clone the bmr gene from the genome of wild-type B. subtilis, 30 ng of DNA of BD224 bacteria was used as template in the polymerase chain reaction (PCR) (GeneAmp Kit; Perkin-Elmer/Cetus). The primers are shown in Fig. 4b .
A single DNA product of the reaction was cloned into the Sma I cloning site of pBluescript KS(+). The insert was cut out by BamHI and HindIII enzymes and recloned in pMK3.
Sequence Analysis. Chain-termination sequencing reactions on double-stranded templates were performed using a T7 sequencing kit (Pharmacia). Standard heptadecameric primers and synthetic heptadecamers complementary to already determined sequence were used as primers.
Sequences cates that this strain is highly resistant to chloramphenicol due to integration of the Cmr gene into the chromosome); E, bacteria bearing the isolated bmr gene in a plasmid (BD224/pMK3-bmr). Open bars, standard medium; hatched bars, medium containing reserpine (5 ,ug/ml). Relative resistances were determined by dividing the minimal inhibitory concentrations (MIC) by the MIC of the given drug for wild-type bacteria in standard medium. The latter had the following values (.g/ml) in this experiment: rhodamine 6G, 0.4; ethidium bromide, 2.0; cetyltrimethylammonium bromide (CTAB), 1.6; puromycin, 15; chloramphenicol, 0.6; tetraphenylphosphonium (TPP), 7.0 ug/ml. These values varied no more than 1.5-fold in different experiments. There were no detectable variations in the relative resistances of the bacterial strains.
RESULTS
We selected B. subtilis BD170 bacteria with stepwise increasing concentrations of one of the substrates of P-glycoprotein, rhodamine 6G. The selected cells able to grow in the presence of the drug at 4 ,ug/ml were subcloned and one of the clones, 1R4, was studied further.
The selected bacteria were resistant not only to rhodamine but also to some other known substrates of P-glycoprotein, such as ethidium bromide, chloramphenicol, and puromycin, as well as to tetraphenylphosphonium and cetyltrimethylammonium bromide, which to our knowledge, have not been shown to be transported by the mammalian MDR pump (Fig.  1) . The sensitivity of the 1R4 bacteria to benzylpenicillin and tetracycline and their growth rate in drug-free medium did not change after the selection (data not shown).
Two inhibitors of mammalian P-glycoprotein, reserpine ( Fig. 1 ) and verapamil (data not shown), significantly increased the sensitivity of wild-type bacteria to toxic compounds. Moreover, they completely reversed the MDR phenotype of 1R4 bacteria, just as they do with mammalian MDR cells.
The mechanism of resistance in the MDR bacteria also turned out to be the same as in MDR mammalian cellsnamely, reduced accumulation of the drugs due to their accelerated efflux. Accumulation of the toxic dye ethidium bromide in 1R4 bacteria was significantly reduced in comparison with wild-type bacteria but could be restored by the addition ofreserpine (Fig. 2a) Fluorescence is a measure of the quantity of cell-associated dye.
Reserpine was added at 5 ;&g/ml. library by plating them on agar containing ethidium bromide (15 ug/ml). Since the resistance gene presumably is able to confer the MDR phenotype when present in multiple copies, the plasmid bearing this gene should exert the same effect. B. subtilis strain BD224 was used as host for the library because it bears a recE4 mutation preventing recombination of plasmid inserts with genomic DNA.
Four clones of bacteria resistant both to ethidium bromide and to erythromycin (pCB20 genetic marker) were selected. The plasmids isolated from these clones bore 10-to 12-kilobase (kb) DNA inserts yielding fragments of similar size when digested with restriction enzymes, thus presumably representing the same fragment of the B. subtilis genome. One of the plasmids, pEBRi, was analyzed further. Molecular hybridization experiments have shown that the fragment of DNA cloned in pEBRi plasmid is indeed, as we assumed, amplified in 1R4 bacteria about 5-10 times, as estimated by the relative intensity of the hybridization signals (Fig. 3) .
Only a part of the DNA fragment cloned in pEBR1 was essential for maintaining the resistance phenotype. The plasmid pEBR24, composed of the pUB110 B. subtilis plasmid and a 4.1-kb Pvu II restriction fragment of the pEBRi insert, also conferred ethidium bromide resistance on wild-type bacterial cells. Cells transformed by pEBR24 were resistant to the same set of drugs as 1R4 cells, and their resistance could be completely reversed by reserpine (Fig. 1) ogous recombination. Cells were transformed with the insert cut from the modified plasmid by Pvu II and then selected for resistance to chloramphenicol (resistance to this drug provided by the Cmr gene is much stronger than that provided by the MDR determinant). The cells selected by this procedure (BD170-lint) were more sensitive to all the drugs of the MDR group (except chloramphenicol) than were the wild-type cells (Fig. 1) . Efflux of ethidium bromide from these cells was at least 10 times slower than from wild-type cells (Fig. 2b) To sequence the MDR genetic determinant, the left Pvu II-EcoRI restriction fragment and the two central EcoRIEcoRI fragments were subcloned separately into E. coli plasmid pUC19. The combined sequence of these fragments contained five ORFs (Fig. 4a) . ORFs A, B, D, and E encoded hydrophilic amino acid sequences and, thus, could hardly represent the potential gene of the membrane multidrug transporter. ORF C (Fig. 4b) , in contrast, encodes a predicted protein of 389 amino acid residues that appears to consist of two highly hydrophobic domains of similar size separated by a hydrophilic region; each domain contains six stretches of hydrophobic amino acids that most likely correspond to transmembrane segments (Fig. 5a ). There is significant sequence homology between the two halves of the protein (data not shown).
A comparison of the sequence of the ORF C protein with the sequence of P-glycoprotein revealed no significant similarity. On the other hand, this protein was closely similar to the tetracycline-effiux proteins encoded by E. coli transposons TnlO and TnJ721 and plasmid pBR322 (Fig. 6) . Their similarity is most evident in their hydropathy profiles, which are nearly identical (Fig. 5) . Besides tetracycline-effiux proteins, the protein encoded by ORF C demonstrated highly significant similarity to some other E. coli membrane transporters: the arabinose and xylose transporters and enzyme II of the phosphotransferase system.
Using the PCR, we amplified the fragment of DNA shown in Fig. 4b from the genome of wild-type B. subtilis and cloned it into the Sma I site of E. coli plasmid pBluescript KS(+).
Sequencing of the cloned PCR fragment showed that the wild-type ORF C and the upstream region of DNA did not differ from the respective sequences cloned previously from 1R4 cells. The cloned PCR fragment was recloned into shuttle vector pMK3 and then transfected into wild-type B. subtilis BD224. After transformation these cells exhibited resistance to ethidium bromide and rhodamine 6G that could be reversed by reserpine (Fig. 1) . These cells were somewhat less resistant to the drugs than the rhodamine-selected cells. This may be either an indication of involvement of some other genes in the resistance of the rhodamine-selected cells, or, more likely, a result of lower expression of the bmr gene in the plasmid-transformed cells. In any case, this result indicates that the amplification of ORF C is responsible, at least partially, for the MDR phenotype of 1R4 bacteria. We The genetic determinant that conferred MDR in the case of B. subtilis selected with rhodamine 6G was of chromosomal, rather than plasmid, origin. We found that these cells have acquired resistance as a result of amplification of the bmr gene. Examples of chromosomal DNA amplification in B. subtilis have been described (10, 16, 17) .
The protein encoded by bmr displays a remarkable sequence similarity to tetracycline-efflux pumps (Tet proteins) and, to a lesser extent, to arabinose-and xylose-H+ symporters. Outward transport oftetracycline by the Tet proteins is apparently coupled to inward transport of H+ (18); the action of these proteins can be blocked by protonophores dissipating the transmembrane pH gradient (19) . The high degree of sequence similarity of the predicted Bmr protein to membrane ion-dependent transport proteins, the ability of bmr to confer efflux-based MDR, the block of the drug efflux in the wild-type cells after the inactivation of this gene, and the strong sensitivity of the drug efflux to protonophores leave practically no doubt that bmr codes for a multidrug efflux transporter. It seems reasonable to suggest that the molecular mechanism of its action is similar to that of Tet proteins, namely H+/drug antiport, though the chemical specificities are different. Tet proteins are specific to tetracycline, while bmr provides resistance not to this antibiotic but to a number of other drugs.
Most intriguing is the remarkable functional similarity between the bacterial and mammalian multidrug transporters. Many drugs can be transported by both Bmr protein and P-glycoprotein. Moreover, both membrane efflux pumps can be inhibited by the same substances, reserpine and verapamil. We failed, however, to detect even slight homology between the two transporters.
There are two possible explanations of the close functional analogy between the bacterial and mammalian multidrug transporters. According to the first hypothesis, the two proteins have similar "multidrug-binding" sites; these sites cannot be detected by the direct sequence comparison because they are formed by the spatial arrangement of the amino acid residues located discontinuously in the polypeptide chains.
An alternative hypothesis, having perhaps more interesting corollaries, assumes that multidrug transporters have no binding sites in the classic sense and that they recognize their substrates by physical rather than purely structural parameters. For example, they might transport to the external medium all moderately hydrophobic substances that occur in the highly hydrophobic membrane environment. The role of a "binding site" in such a transporter can be performed by a relatively hydrophilic part of the protein exposed into the lipid bilayer. In this case, the repertoire of substrates and competitive inhibitors should be determined mainly by the physical properties of the substances themselves and only slightly by the structure of transporter. If this hypothesis is correct, then the functional analogy between the structurally distinct bacterial and mammalian multidrug transporters is not surprising.
In conclusion, our results demonstrate that the transport of multiple drugs can be effected not only by P-glycoprotein or P-glycoprotein-related molecules but also by the bacterial Bmr protein belonging to another family of membrane transporters. Since the genetic and biochemical experiments are potentially easier to perform with bacteria than with mammalian cells, we anticipate that further study of the Bmr protein will contribute to the understanding ofthe mechanism of low-specificity membrane transport.
